Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is an essential enzyme in the folate biosynthesis pathway of bacteria and lower eukaryotes. It catalyzes the transfer of a pyrophosphate group from ATP to 6-hydroxymethyl-7,8-dihydropterin (HMDP), producing 6-hydroxymethyl-7,8-dihydropterin-pyrophosphate (DHPPP). This reaction represents the first committed step in de novo folate synthesis. HPPK is an attractive target for antimicrobial drug development because mammals do not synthesize folates de novo.
Inhibition of folate biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK).